Spots Global Cancer Trial Database for Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
Official Title: A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Study ID: NCT01204177
Conditions
Interventions
Study Description
Brief Summary: This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations. Efficacy of the combination BAY86-9766 and sorafenib will be determined by disease control rate, overall survival, time to progression, response rate and duration of response.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Shatin, New Territories, Hong Kong
, Hong Kong, , Hong Kong
, Jung-gu, Daegu Gwang''yeogsi, Korea, Republic of
, Goyang-si, Gyeonggido, Korea, Republic of
, Busan, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Singapore, , Singapore
, Singapore, , Singapore
, Kaohsiung, , Taiwan
, Tainan, , Taiwan
, Tainan, , Taiwan
, Taipei, , Taiwan
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
